Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Astrocytoma: early-phase trial registry
10 of 20 indexed Astrocytoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 10 currently recruiting · #848 of 28,707 conditions by registered trial count
Astrocytoma: 20 US clinical trials tracked, 10 recruiting.
Astrocytoma is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is James Markert, MD, running 1 of these trials.
Enrollment posture brief
Registry condition astrocytoma
OPEN 10 | RECR 50% | LATE 1 | EARLY 14 | RANK #848 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Astrocytoma lists 10 open slots (50% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Astrocytoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Astrocytoma is recruiting above its size-band peers.
10 of 20 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Astrocytoma trials is spread across many organizations.
James Markert, MD accounts for 1 of 20 trials (5%). 20 distinct sponsors appear on at least one study for this condition label.
-
Most Astrocytoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 20 trials that report a genuine target (sentinel values excluded). 18 of those (90%) plan for fewer than 100 participants.
-
Astrocytoma research is mostly interventional.
19 interventional and 1 observational studies make up this index (95% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
FearLess in NeuroOncology
Virginia Commonwealth University
NCT06989086
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics
NCT05879367
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
NCT06161974
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Stephen Bagley, MD, MSCE
NCT05345002
Venous Thromboembolism Prevention in Outpatients With Glioma
University of Vermont Medical Center
NCT05683808
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT06344130
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
NCT03911388
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Columbia University
NCT06108206
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT05686798
Implantable Microdevice In Primary Brain Tumors
Oliver Jonas
NCT04135807
Pediatric Long-Term Follow-up and Rollover Study
Novartis Pharmaceuticals
NCT03975829
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Dana-Farber Cancer Institute
NCT03152318
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Institut de Recherches Internationales Servier
NCT05484622
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
NCT05236036
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
University of California, San Francisco
NCT03739372
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato
NCT05561374
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
James Markert, MD
NCT06614855
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Wake Forest University Health Sciences
NCT02747407
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Emory University
NCT01331135
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Washington University School of Medicine
NCT05393258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Astrocytoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Astrocytoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Astrocytoma page
20 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Astrocytoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- James Markert, MD sponsors the most Astrocytoma trials on record, review their full trial history before evaluating a specific study. See James Markert, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Astrocytoma condition card totals 20 registered trials; most-linked intervention Temozolomide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.